- Home
- FSFG vs BWAY Comparison
FSFG vs BWAY Comparison
Compare FSFG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- BWAY
- Stock Information
- Founded
- FSFG 2008
- BWAY 2003
- Country
- FSFG United States
- BWAY Israel
- Employees
- FSFG N/A
- BWAY N/A
- Industry
- FSFG Savings Institutions
- BWAY Medical/Dental Instruments
- Sector
- FSFG Finance
- BWAY Health Care
- Exchange
- FSFG Nasdaq
- BWAY Nasdaq
- Market Cap
- FSFG N/A
- BWAY 177.4M
- IPO Year
- FSFG 2008
- BWAY 2019
- Fundamental
- Price
- FSFG $25.18
- BWAY $10.69
- Analyst Decision
- FSFG Buy
- BWAY Strong Buy
- Analyst Count
- FSFG 1
- BWAY 3
- Target Price
- FSFG $31.00
- BWAY $13.17
- AVG Volume (30 Days)
- FSFG 11.8K
- BWAY 50.5K
- Earning Date
- FSFG 02-04-2025
- BWAY 03-05-2025
- Dividend Yield
- FSFG 2.40%
- BWAY N/A
- EPS Growth
- FSFG 66.39
- BWAY N/A
- EPS
- FSFG 1.98
- BWAY 0.04
- Revenue
- FSFG $68,091,000.00
- BWAY $38,631,000.00
- Revenue This Year
- FSFG N/A
- BWAY $388.82
- Revenue Next Year
- FSFG $2.77
- BWAY $18.70
- P/E Ratio
- FSFG $12.65
- BWAY $137.57
- Revenue Growth
- FSFG N/A
- BWAY 34.19
- 52 Week Low
- FSFG $14.55
- BWAY $4.61
- 52 Week High
- FSFG $30.94
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- FSFG 41.87
- BWAY 62.56
- Support Level
- FSFG $24.77
- BWAY $10.08
- Resistance Level
- FSFG $26.12
- BWAY $11.25
- Average True Range (ATR)
- FSFG 0.77
- BWAY 0.37
- MACD
- FSFG 0.08
- BWAY 0.15
- Stochastic Oscillator
- FSFG 33.00
- BWAY 72.96
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.